Plain-English translation of NCT07266480 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing , a new immunotherapy medication designed to help prevent esophageal squamous cell cancer from coming back after surgery. Researchers want to learn whether the medication is safe and effective when given to patients after they've had their cancer surgically removed. About 142 patients will participate in this study, which is currently recruiting participants.
Even after surgery successfully removes esophageal cancer, cancer can sometimes return. Doctors are testing this medication to see if it can help train the immune system to prevent that recurrence and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive intravenous infusions of the medication every three weeks for about one year (17 cycles total). You'll need to visit the hospital or clinic for each infusion and have regular blood tests and check-ups to monitor how the treatment is working and watch for side effects. The study team will follow your health closely throughout the treatment period and beyond.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Hebei Medical University Fourth Hospital
Enrollment target
~142 participants
Started
September 2025
Primary completion
September 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ziqiang Tian
Hebei Medical University Fourth Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.